Key Financial Figures
Revenue Performance:
- Q2 FY27 revenue: INR489 crores (59% YoY growth from INR308 crores in Q2 FY26)
- Sequential growth: 11% over Q1 FY27
- H1 FY27 healthcare network revenue: INR895 crores
Revenue Breakdown by Vertical:
- RetailerShakti (B2B): INR429 crores (60% YoY growth, 18% sequential growth)
- SastaSundar (B2C): INR55 crores (39% YoY growth, 6 consecutive quarters of growth from INR32 crores in Q1 FY26)
- Diagnostic: INR0.8 crores
Margin Performance:
- Gross margin: INR40.7 crores (8.3% of revenue)
- YoY margin expansion: 80 bps from 7.5%
- Sequential margin expansion: 40 bps from 7.9%
- Gross margin grew 77% YoY vs revenue growth of 59%
Operating Metrics:
- Operating expenditure: 10.8% of revenue (down 160 bps YoY from 12.4%, down 80 bps sequentially from 11.6%)
- EBITDA loss: INR17.2 crores (3.5% of revenue)
- YoY EBITDA improvement: 170 bps from 5.2% loss
- PAT loss: INR12.7 crores (2.6% of revenue) vs INR15.4 crores loss (5% of revenue) in Q2 FY26
Working Capital:
- Net working capital: 23 days (down from 28 days in June, 18% reduction)
- Inventory: 35 days
- Receivables: 2 days
- Payables: 13 days
- Working capital at 6% of revenue
Cost Structure:
- Employee cost: INR31 crores (up from INR27.7 crores in previous quarter)
- Depreciation and finance costs: 0.8% of revenue combined
Strategic Updates
RetailAir Launch:
- Mobile-first billing software for retail pharmacies launched on Google Play
- Designed for immediate billing without inventory setup requirement
- Features include low stock alerts, near-expiry alerts, dead stock identification, fast mover tracking
- AirPad feature automatically generates reorder lists integrated with RetailerShakti
- GST-ready filing capabilities
- Serves 80,000 retail pharmacies through RetailerShakti
Technology Infrastructure:
- Fulfillment centers use AI-led picking, sorting, and routing
- 90% of orders delivered within 24 hours
- New centers being commissioned on automated stack
- AI roadmap includes intelligent medicine counseling, consultation validation, personalized wellness recommendations, smart health records
Geographical Expansion:
- New offices opened in Bhubaneswar, Odisha, Patna, and Jharkhand
- Current fulfillment centers: Baruipur (West Bengal), Assam, Noida
- Planned capacity expansion: 5.95 lakh square feet additional capacity
- Specific projects: Udaipur (80,000 sq ft), Lucknow (80,000 sq ft), Patna (20,000 sq ft initially, then 1.2 lakh sq ft), Bhubaneswar (20,000 sq ft initially, then 1.2 lakh sq ft), Guwahati (75,000 sq ft)
- West Bengal fulfillment center upgraded and automated
- Noida warehouse upgraded to double capacity
JITO Private Label:
- Q2 performance: INR2.2 crores revenue with ~60% gross margin
- 170% growth compared to Q1
- 52 franchise outlets live, 81 in pipeline
- Over 1,000 healthcare SKUs
- Target: 13% revenue contribution from JITO by FY29-30
- Next quarter target: INR6-10 crores revenue
Merger Update:
- Merger application pending SEBI observation letter
- Expected SEBI observation by end of December 2026
- NCLT process expected to take 4-6 months after SEBI approval
- Targeted effective date: April 1, 2026
Management Commentary
Growth Strategy:
- Targeting 30%+ compounded growth
- Focus on Tier 2 and Tier 3 markets (76% of SastaSundar business, 66% of RetailerShakti business)
- Belief in healthcare distribution consolidation in India
- Emphasis on data-driven distribution rather than mere box-moving
- Category expansion into preventive care, devices, wellness, personal care
Profitability Approach:
- Deliberate choice to avoid easy profitability through treasury investments (potential INR50 crores/year)
- Organic growth investment cost: ~30% of incremental revenue generated
- Investment in technology and AI expensed through P&L
- Expected margin expansion through: 2% gross margin expansion, 2% operating cost reduction through scale
- Gross margin target progression: 8.5-8.6% in FY27, 9-10% in FY28, 10-11% in FY29
Capital Discipline:
- Cash-based model with 2-day receivables cycle
- No meaningful debt
- 90%+ purchases directly from pharmaceutical companies
- No payment for purchase rights
- Treasury utilization focused on business investment
Q&A Highlights
Distribution Advantages: Large distributors get better margins from bulk purchases, lower operational costs through scale, and market diversification benefits.
NBFC Partnerships: Company has partnered with 2 national banks and NBFCs for retailer working capital financing, but adoption slowed by documentation requirements.
Healthbuddy Economics: Healthbuddy franchisees retain ~4% commission on sales delivered through app.
Capacity Planning: Existing fulfillment centers equipped to handle projected growth for 18 months (West Bengal) and 3-4 years (Noida, Guwahati).
Gross Margin Levers: Improved sourcing, private label mix, channel optimization, data monetization, logistics revenue. Data monetization expected to contribute ~1% to gross margin.
AI Development: AI consultation/counseling features expected to launch by October-November 2027.
Revenue Target Revision: FY29-30 revenue target revised from INR6,000 crores to INR4,900 crores due to JITO brand mix (lower pricing but higher margins).